A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

NCT07672223 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SYS6010
DRUG: Enlonstobart
DRUG: Tislelizumab
DRUG: Toripalimab ±+platinum-based doublet chemotherapy
DRUG: Durvalumab
DRUG: Pembrolizumab
DRUG: Nivolumab

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.